ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1053

Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo

Kristina Clark1, Corrado Campochiaro 1, Nataliya Gak 1, Emma Derrett-Smith 1 and Christopher Denton 2, 1University College London, London, United Kingdom, 2University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Gene Expression, Morphea, Scleroderma, systemic sclerosis and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have examined whole skin biopsy gene expression by RNAseq in a rare subgroup of scleroderma with both systemic sclerosis (SSc) and concurrent keloidal morphea (KM).  We hypothesised that this subtype of localised scleroderma would provide exceptional insight into fibroblast activation in vivo relevant to skin fibrosis in systemic sclerosis and suggest new potential molecular markers for classification.

Methods: 4mm skin biopsies were taken from forearm skin of SSc cases classified as limited (lcSSc) (n=5) or diffuse (dcSSc) (n=7).  All patients met ACR/EULAR criteria for classification of SSc. In 4 cases there was concurrent KM and 4mm skin were also taken from these lesions.  Control biopsies were taken from forearm skin of healthy individuals (HC) (n=4).  Whole genome expression analysis was performed by RNAseq.  Data were normalised and scaled. Gene expression analysis was undertaken and differentially expressed genes were compared across the clinical subgroups using ANOVA with Benjamini-Hochberg post-hoc correction. The 500 most differentially expressed genes were identified, and unsupervised clustering was performed using CIMminer (Bethesda, Maryland, USA). Integration of the candidate genes from ANOVA, and principal component analysis (PCA) was carried out to identify instructive genes for a molecular classifier. 

Results: RNAseq identified over 13000 expressed genes. PCA discriminated 4 unique clusters, with keloidal morphea and HCs being the most distinct. PC1 accounted for 33% and PC2 for 22% of variation. Initial analysis identified over 3000 significantly different genes expressed by paired analysis. The 500 most significantly differentially expressed genes (all with p< 0.001) were selected. Unsupervised hierarchical clustering of gene expression based on these results, showed clear clustering of the keloidal morphea group, and the HCs. The majority of lcSSc and dcSSc patients clustered to their patient subgroups (Figure 1). Correlation between ANOVA and PCA results highlighted 100 key genes shared across both analysis results.  These included genes upregulated in SSc: SFRP4, THY1, COMP, ADAM12, THBS4, ADAMTS12 (table 1) and others with lower expression than in HC: WIF1, KLF5.  These include several implicated in pathogenesis or included in recent candidate biomarkers for skin disease in SSc.

Conclusion: We show the high value of RNAseq and the unique strength using skin biopsies from SSc with concurrent keloidal morphea, histologically characterised by dense fibro-proliferation, to define profibrotic genes relevant to SSc.   This provides powerful insight into pathogenesis and candidate molecular markers for classification across the scleroderma spectrum.

Figure 1: Unsupervised hierarchical clustering of differentially genes across scleroderma spectrum confirms potential utility of these genes in subset classification. Key: HC -healthy control-, KM -keloidal morphea-

Table 1: Sample scleroderma genes showing altered expression in keloidal morphea and systemic sclerosis.


Disclosure: K. Clark, None; C. Campochiaro, None; N. Gak, None; E. Derrett-Smith, None; C. Denton, Actelion, 5, Actelion Pharmaceuticals, 5, Actelion, GlaxoSmithKline, Bayer, Sanofi, lnventiva, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CSL Behring, UCB, Leadiant Biosciences, 5, Bayer, 5, Boehringer Ingelheim, 5, Bristol Myers Squibb, 5, Bristol-Myers Squibb, 5, Corbus Pharmaceuticals, 5, CSL Behring, 2, 5, GlaxoSmithKline, 2, 5, Inventiva, 2, 5, Leadiant Biosciences, 2, 5, lnventiva, 5, Pfizer, 5, Roche, 5, Sanofi, 5, UCB, 5.

To cite this abstract in AMA style:

Clark K, Campochiaro C, Gak N, Derrett-Smith E, Denton C. Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/parallel-analysis-of-systemic-sclerosis-and-keloidal-morphea-skin-biopsies-delineates-the-hallmark-profibrotic-gene-expression-profile-for-scleroderma-in-vivo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parallel-analysis-of-systemic-sclerosis-and-keloidal-morphea-skin-biopsies-delineates-the-hallmark-profibrotic-gene-expression-profile-for-scleroderma-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology